III-001 Nicolas Luyckx
Model-Informed Precision Dosing of Tacrolimus in Lung Transplantation Early After Surgery Using Model-Predictive Control in the tdmore Framework
Thursday 09:50-11:20 |
III-002 Moustafa M. A. Ibrahim
The reference corrected VPC – A more intuitive model diagnostic
Thursday 09:50-11:20 |
III-003 Panos Macheras
Understanding the gastrointestinal absorption of drugs using Physiologically Based Finite Time Pharmacokinetic (PBFTPK) Models: Focus on Biowaivers
Thursday 09:50-11:20 |
III-004 Paolo Magni
Combining Reinforcement Learning and PK-PD models to personalize multiple drug administration: an application to Axitinib-Anti-Hypertensive treatment in metastatic renal cancer patients
Thursday 09:50-11:20 |
III-005 SOPHIE MAGREAULT
What clindamycin dose for which administration route in case of combination with rifampicin?
Thursday 09:50-11:20 |
III-006 Wen Yao Mak
Population repeated time-to-event analysis of peritonitis in end-stage renal failure: Predicting the natural progression and infection risk through nationwide registry data
Thursday 09:50-11:20 |
III-007 Victor Mangas-Sanjuan
Pharmacometric characterization of the reserpine-induced fibromyalgia model in rats to support a model-informed dosing regimen strategy for alternative disease status conditions
Thursday 09:50-11:20 |
III-008 Jialin Mao
Human PK prediction of Kras G12C covalent inhibitors: GDC-6036, AMG-510 and MRTX-849 using PBPK approach
Thursday 09:50-11:20 |
III-009 Mathilde Marchand
Comparison of tumor dynamics models and tumor growth inhibition metrics in support of decisions in early Phase Ib/II clinical oncology studies
Thursday 09:50-11:20 |
III-010 Hadija Marchiori
A Nonlinear Mixed Effect model of the LNA-i-miR-221 kinetics in rats for predicting key parameters of human kinetics via allometric scaling
Thursday 09:50-11:20 |
III-011 John Maringwa
Assessing Approaches for Handling Missing Precision Measures Issue in Model-Based Meta Analysis (MBMA)
Thursday 09:50-11:20 |
III-012 Fatima Zahra Marok
Parent-Metabolite Physiologically Based Pharmacokinetic Modeling of Mirtazapine during Drug-Drug- and Drug-Gene-Interactions
Thursday 09:50-11:20 |
III-013 Eleonora Marostica
Population analysis of MG-ADL total score for efgartigimod Phase 3 study in myasthenia gravis patients: application of a bounded-integer model
Thursday 09:50-11:20 |
III-014 Lara Marques
Toward Personalized Salbutamol Therapy: Validating Virtual Patient-Derived Population Pharmacokinetic Model with Real-World Data
Thursday 09:50-11:20 |
III-015 Silvia Marquez-Megias
Development of population pharmacokinetic models using informative priors in clinical settings
Thursday 09:50-11:20 |
III-016 Carl Julius Martensen
Data-Driven Discovery of Interpretable Feedback Mechanisms in Acute Myeloid Leukaemia using DeepPumas
Thursday 09:50-11:20 |
III-017 Enrico Mastrostefano
Integrating PKPD and Agent-Based Modeling to Explore Tuberculosis Relapse after Treatment.
Thursday 09:50-11:20 |
III-018 Andres Mazariegos Herrera
Weight-band based simplification of oral allometric miltefosine dosing in pediatric patients with visceral leishmaniasis in Eastern Africa
Thursday 09:50-11:20 |
III-019 Anna Mc Laughlin
Model-informed early clinical development of BI-1808, a novel monoclonal antibody to tumor necrosis factor receptor 2
Thursday 09:50-11:20 |
III-020 Denis Menshykau
Population PK modeling of certolizumab pegol in pregnant women with chronic inflammatory diseases.
Thursday 09:50-11:20 |
III-021 Matilde Merino-Sanjuán
Effects of number of time points and variability on bootstrap f2 method for the comparison of dissolution profiles
Thursday 09:50-11:20 |
III-022 Assil MERLAUD
To quantify the association between tumor dynamics and overall survival across cancers: a Bayesian meta-analysis
Thursday 09:50-11:20 |
III-023 Lyndsey Meyer
Advancing Quantitative Systems Pharmacology (QSP) Disease Progression Modeling with Real-World Data: Applications for Patients with Unintentional Weight Loss
Thursday 09:50-11:20 |
III-024 Anna Mishina
A comparative benchmark study of empirical tumor size models in NSCLC clinical data
Thursday 09:50-11:20 |
III-025 Sarang Mishra
PBPK modelling based estimation of safe, and effective Molnupiravir doses for pediatric subpopulations against SARS-CoV-2
Thursday 09:50-11:20 |
III-026 Adrien Mitard
Modelling antibody levels impact on infection and SARS-CoV2 replication
Thursday 09:50-11:20 |
III-027 Laurynas Mockeliunas
Model-based assessment of early bactericidal activity of rifampicin in combination with meropenem plus amoxicillin/clavulanate among adults with rifampicin-resistant pulmonary tuberculosis
Thursday 09:50-11:20 |
III-028 Juma Ayubu MOHAMEDI
Cumulative exposure to infliximab during induction therapy predict remission in patients with Crohn’s disease and ulcerative colitis
Thursday 09:50-11:20 |
III-029 Zeyar Mohammed Ali
Evaluation of extrapolation potential of IMPRES-M, a non-parametric Impulse-Response Modeling framework when applied to pharmacokinetic profiles of different dosing frequencies
Thursday 09:50-11:20 |
III-030 Marcel Mohr
Integrated In Vitro/In Silico Systems Immunology Model to Quantify Drug-Induced Changes in the Immune Response after Influenza A Virus Infection – A Blueprint for the Preclinical Assessment and Clinical Translation of Infection Risks for Biologics
Thursday 09:50-11:20 |
III-031 James Morse
Sevoflurane Pharmacokinetics and Pharmacodynamics in Adults During General Anaesthesia
Thursday 09:50-11:20 |
III-032 Felix Müller
Understanding variability in microdialysis measurements: introducing a combined calibration approach for piperacillin and tazobactam in LPS-induced septic piglets
Thursday 09:50-11:20 |
III-033 Veronika Musatova
Cis-binding of bispecific antibodies: effect of additional valency and dose on the antibody-target complexes formation on the example of antibody CTX8371
Thursday 09:50-11:20 |
III-034 Goutam Nair
Development of QSP platform model for predicting clinical efficacy and CRS incidence of CD3 bispecifics in STEAP1 Prostate Cancer
Thursday 09:50-11:20 |
III-035 Supichaya Narongchartsopon
Implications of the changes in the pharmacokinetics of raltegravir in pregnant and post-partum women undergoing antiretroviral therapy against HIV infection.
Thursday 09:50-11:20 |
III-036 Adam Nasim
Discovering Intrinsic PK/PD Models Using Physics Informed Neural Networks
Thursday 09:50-11:20 |
III-037 Yomna Nassar
Simulation-based evaluation of combined Likelihood Ratio Test (cLRT) and Multiple Comparison Procedure (MCP) approaches to identify a dose-response relationship in the oncology setting under different study design variables
Thursday 09:50-11:20 |
III-038 Bach NGUYEN
Mechanistic model of antibody response, SARS-CoV-2 viral loads and genetic mutation burden to optimise molnupiravir dosing
Thursday 09:50-11:20 |
III-039 Linh Nguyen Phuong
Circulating cell-free DNA size distribution as a prediction marker for early progression undergoing immune checkpoint inhibitors
Thursday 09:50-11:20 |
III-040 Chiara Nicolò
Simulating maximum tolerated dose-finding oncology trials using the InSilicoTrials cloud-based platform
Thursday 09:50-11:20 |
III-041 Antonina Nikitich
An integrative physiologically-based model of T lymphocyte homeostasis and exogenously administered T cell kinetics
Thursday 09:50-11:20 |
III-043 Chen Ning
Physiologically based pharmacokinetic modeling and simulation of a promising novel antiplatelet drug vicagrel and its metabolites
Thursday 09:50-11:20 |
III-044 Jeein Noh
Machine Learning for Antibiotic-Induced Nephrotoxicity Prediction in Korean Hospitalized Patients
Thursday 09:50-11:20 |
III-045 Pär Nordell
Predicting in vivo disposition of OATP substrates from in vitro kinetics using mechanistic PBPK modelling
Thursday 09:50-11:20 |
III-046 Nuo Xu
Population Pharmacokinetics and Safety Assessment of Rifapentine in Chinese Children to Inform Dosing Recommendations for Latent Tuberculosis Infection
Thursday 09:50-11:20 |
III-047 Katharina Och
Evaluation of a pharmacokinetic model of certoparin in patients with deep vein thrombosis and severe renal insufficiency
Thursday 09:50-11:20 |
III-048 Amaury O'Jeanson
Data-driven model selection for model-informed precision dosing: a case study with vancomycin
Thursday 09:50-11:20 |
III-049 Ochuko Orherhe
Pharmacometric modelling to describe pharmacokinetics and exposure-response of ivermectin in adolescent patients infected with Trichuris trichiura
Thursday 09:50-11:20 |
III-050 Marije Otto
Characterization of absorption kinetics of oral esketamine in healthy volunteers
Thursday 09:50-11:20 |
III-051 David Outland
Towards a vertex based mechanical model of vascular endothelial cell morphology in the context of the interaction of blood flow and vascular geometry
Thursday 09:50-11:20 |
III-052 Joanneke Overbeek
Population pharmacokinetics of cobicistat in once and twice daily regimens in various populations
Thursday 09:50-11:20 |
III-053 Agustos Cetin Ozbey
PBPK modeling based clinical dose adaptation in liver cirrhosis patients for seven CYP and UGT enzyme substrates
Thursday 09:50-11:20 |
III-054 Eirini Panoilia
A model based meta-analysis of the placebo response for EASI and pruritus NRS scores in moderate to severe atopic dermatitis
Thursday 09:50-11:20 |
III-055 Orestis Papatryfonos
Modelling of tumour growth with respect to the use of anti-cancer agents
Thursday 09:50-11:20 |
III-056 Joanna Parkinson
A streamlined, semi-automated workflow allows quick and efficient QTc and other ECG intervals modeling assessment, saving time and cost.
Thursday 09:50-11:20 |
III-057 Zinnia Parra-Guillen
Optimal study design for pharmacokinetic modeling of teicoplanin in critically ill children, including those undergoing Continuous Renal Replacement Therapy
Thursday 09:50-11:20 |
III-058 Madison Parrot
A Minimal PBPK Model to Predict Biodistribution of Silica Nanoparticles in Mice
Thursday 09:50-11:20 |
III-059 Blaise Pasquiers
Translational modelling of tumor growth inhibition and treatment resistance for a molecule targeting apoptosis pathway
Thursday 09:50-11:20 |
III-060 BELA PATEL
Development and benchmarking of non-generative and generative natural language processing approaches for AI-assisted pharmacometric literature curation
Thursday 09:50-11:20 |
III-061 Anu Patel
Comparison of oxazolidinones’ exposure-response for the treatment of tuberculosis
Thursday 09:50-11:20 |
III-062 Noel Patson
Natural disease progression model with transition probabilities to describes the continuum of Alzheimer’s disease
Thursday 09:50-11:20 |
III-063 Sophie Peigné
Population pharmacokinetic analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-targeting antibody-drug conjugate
Thursday 09:50-11:20 |
III-064 Zorica Pejčić
Joint population pharmacokinetic model for clopidogrel and its inactive carboxylic acid metabolite
Thursday 09:50-11:20 |
III-065 Mariana Pereira
Etravirine's Pharmacokinetics Explored: PBPK Modeling and DDI Analysis with Efavirenz for Cancer Treatment
Thursday 09:50-11:20 |
III-066 Carlos Perez-Ruixo
A Mechanism-Based PK/PD Model for Posdinemab (JNJ-63733657), a Humanized Monoclonal Antibody Targeting pTau, in healthy and Alzheimer’s Disease Subjects
Thursday 09:50-11:20 |
III-067 Sara Peribanez
A physiologically-based pharmacokinetic model to predict systemic and organ exposure for colorectal cancer drugs in clinical settings
Thursday 09:50-11:20 |
III-068 Yuan Pétermann
Population pharmacokinetic model of encorafenib and binimetinb in real life settings
Thursday 09:50-11:20 |
III-069 Kristin C. Carlsson Petri
TransCon CNP (Navepegritide): A semi-mechanistic model to describe the prolonged half-life of C-type natriuretic peptide through TransConTM technology
Thursday 09:50-11:20 |
III-070 Zvonimir Petric
Population Pharmacokinetic Model of Apovincaminic Acid (AVA) — an Exposure Proxy of Vinpocetine
Thursday 09:50-11:20 |
III-071 Thao Pham
DeepARV-ChemBERTa: Ensemble Deep Learning to Predict Drug-Drug Interaction of Clinical Relevance with Antiretroviral Therapy
Thursday 09:50-11:20 |
III-072 Anh Duc Pham
Population plasma and tissue pharmacokinetics of linezolid in healthy volunteers and septic patients
Thursday 09:50-11:20 |
III-073 Morgane PHILIPP
Extension of the covariate clinical relevance determination in population pharmacokinetic analyses to the Least Absolute Shrinkage and Selection Operator (LASSO) and to Genetic Algorithm (GA) approaches
Thursday 09:50-11:20 |
III-074 Cesar Pichardo
The International Society of Pharmacometrics’ Special Interest Group on Quantitative Systems Pharmacology (ISoP QSP SIG): Recent Developments and Future Vision
Thursday 09:50-11:20 |
III-075 Antoine Pitoy
Estimation of phase III trial outcome in oncology using joint models of longitudinal biomarker and time-to-event data
Thursday 09:50-11:20 |
III-076 Vikram Prabhakar
A comprehensive multi-scale in silico approach for predicting antibody-drug conjugate clinical efficacy across oncological indications
Thursday 09:50-11:20 |
III-077 Laure-Hélène Préta
Antidepressants transplacental transfer modeling using ex vivo perfusion of isolated human placenta cotyledon
Thursday 09:50-11:20 |
III-078 Alicja Puszkiel
Impact of resting energy expenditure on nivolumab pharmacokinetics and survival in metastatic non-small cell lung cancer patients
Thursday 09:50-11:20 |
III-079 Luyuan Qi
A generic modeling framework for dose regimen optimization and patient selection in radioligand therapy
Thursday 09:50-11:20 |
III-081 Elba Raimundez Alvarez
Evaluation of automated model development workflows for population pharmacokinetic models
Thursday 09:50-11:20 |
III-082 Chetan Rathi
Translational PK-Tumor Growth Inhibition (TGI) modeling of type 1 PRMT and PRMT5 inhibitor combination to predict clinical response
Thursday 09:50-11:20 |
III-083 Anne Ravix
Numerical validation of Tucuxi, a promising new Bayesian adaptation tool
Thursday 09:50-11:20 |
III-084 Ibtissem Rebai
mlcov: New Machine Learning Based R package for Covariate Selection
Thursday 09:50-11:20 |
III-085 Javier Reig-López
Assessment of bioequivalence outcomes of oral formulations containing racemic ibuprofen through a chiral physiologically-based pharmacokinetic model
Thursday 09:50-11:20 |
III-086 Freek Relouw
Towards an Inflammation Simulation Model: Development and Validation of a Mathematical Model of the Human Inflammatory Response to Acute and Prolonged Lipopolysaccharide Exposure
Thursday 09:50-11:20 |
III-087 Quentin Renou
External evaluation of a population pharmacokinetic (POP-PK) model of Cabotegravir HIV-1-infected patients treated with long-acting Cabotegravir/Rilpivirine (LA CAB-RPV)
Thursday 09:50-11:20 |
III-088 Juan Eduardo Resendiz Galvan
What is the effective concentration of dolutegravir? A pharmacokinetic/pharmacodynamic analysis.
Thursday 09:50-11:20 |
III-089 Silke Retlich
Leveraging Model-Based Meta-Analysis to Benchmark Chronic Kidney Disease Treatments: A Focus on Kidney Function and Proteinuria Endpoints
Thursday 09:50-11:20 |
III-090 Mar Ribera Armengol
Causal considerations in Exposure-Response and Population PK covariate analysis
Thursday 09:50-11:20 |
III-091 Pascale Rietveld
The effect of pH on intratumoural docetaxel release from polymeric nanoparticle CPC634
Thursday 09:50-11:20 |
III-092 Camille Riff
Pharmacokinetics of inhaled AZD4604 supports lack of JAK1 systemic activity at therapeutic dose
Thursday 09:50-11:20 |
III-093 Matthew Riggs
bbr.bayes: An Open-Source Tool to Facilitate an Efficient, Reproducible Bayesian Workflow Using NONMEM
Thursday 09:50-11:20 |
III-094 Elena Righetti
A mechanistic model of pure and lipid-mediated alpha-synuclein aggregation to advance therapeutic strategies against Parkinson’s disease
Thursday 09:50-11:20 |
III-095 François Riglet
Successful Establishment of Optimal Biological Dose (OBD) through PK/PD Modeling of BCL2/BIM Complex Disruption in Clinical Trials using a BCL-2 Inhibitor.
Thursday 09:50-11:20 |
III-096 Donnia Robins
Elucidating parametric first and second-order effects in PBPK models for special scenarios using a GSA-based approach
Thursday 09:50-11:20 |
III-097 Christelle Rodrigues
Optimizing the Dose Escalation of a new anti-CD73 monoclonal antibody for target Inhibition: A Comprehensive Preclinical and Clinical Modelling Approach
Thursday 09:50-11:20 |
III-098 Karine Rodriguez-Fernandez
Estimation of a sensitive range of dose-adjusted FaSSIF solubility to predict the food effect on BCS II/IV drugs
Thursday 09:50-11:20 |
III-099 Maša Roganović
External evaluation of published population pharmacokinetic models of adalimumab in inflammatory bowel disease patients
Thursday 09:50-11:20 |
III-100 Davide Ronchi
Translational modeling of tumor response to treatment: bridging preclinical to clinical studies
Thursday 09:50-11:20 |
III-101 Chiara Roversi
Integrated Population PK and PBPK Modelling Approaches of IAMA-6 Plasma Concentrations following Oral, Intraperitoneal and Intravenous Administrations in Three Different Preclinical Species for First in Human Dose Prediction
Thursday 09:50-11:20 |
III-102 Karen Rowland Yeo
Relative impact of CYP2D6 phenotype, physiological changes and hepatic extraction ratio on drug exposure during pregnancy
Thursday 09:50-11:20 |
III-104 Mark Sale
Performance of Machine Learning Algorithms for Model Selection
Thursday 09:50-11:20 |
III-105 Ayatallah Saleh
Evaluating the contribution of Urine Data to PopPK Models in Renal Impairment: A Case Study
Thursday 09:50-11:20 |
III-106 Sergio Sánchez Herrero
Individualized Prediction of Gentamicin Concentration in Neonates: A Multimodal Approach of PBPK Modeling and Machine Learning
Thursday 09:50-11:20 |
III-107 Aymara Sancho
Does shrinkage on exposure metrics truly impair E-R analysis?
Thursday 09:50-11:20 |
III-108 Andrew Santulli
nonmem2mrgsolve: An R package for Automated NONMEM to mrgsolve Translation
Thursday 09:50-11:20 |
III-109 Raphaël Saporta
Pharmacokinetic-pharmacodynamic modelling to characterize the time-course of meropenem effect in vivo on bacteria with high MIC
Thursday 09:50-11:20 |
III-110 Adriana Savoca
Integration of clinical data and mechanistic model simulations highlights key parameters for design and selection of successful ADCs
Thursday 09:50-11:20 |
III-111 Sharon Sawe
Population pharmacokinetics of delamanid in adults treated for rifampicin-resistant tuberculosis: effect of pregnancy.
Thursday 09:50-11:20 |
III-112 Franziska Schädeli Stark
Performance evaluation of the Automatic Model Development (AMD) tool with real population pharmacokinetic datasets from clinical drug development projects
Thursday 09:50-11:20 |
III-113 Carmine Schiavone
Understanding Population Heterogeneity in Vaccine-induced Immunity: A Mechanistic Model for Immune Fingerprinting
Thursday 09:50-11:20 |
III-114 Verena Schöning
Total and unbound flucloxacillin population pharmacokinetics in patients with Staphylococcus aureus bloodstream infection
Thursday 09:50-11:20 |
III-116 Clarisse Schumer
Building a model from comparison of SARS-CoV-2 viral dynamics model proposed since 2020: what are the main differences?
Thursday 09:50-11:20 |
